Shirley Chuang

TL;DR: Methylphenidate was often efficacious in treating hyperactivity associated with pervasive developmental disorders, but the magnitude of response was less than that seen in typically developing children with attention-deficit/hyperactivity disorder.

TL;DR: MPH-IR, delivered in 2.5, 5, and 7.5-mg doses t.i.d., produced significant reductions on ADHD symptom scales in preschoolers compared to placebo, although effect sizes were smaller than those cited for school-age children on the same medication.

TL;DR: Risperidone led to significant improvements in the restricted, repetitive, and stereotyped patterns of behavior, interests, and activities of autistic children but did not significantly change their deficit in social interaction and communication.

TL;DR: Methylphenidate 3- to 5-year-old children with attention-deficit/hyperactivity disorder (ADHD) during 1 year of treatment with methylphenidate (MPH) suffered from emotional outbursts, difficulty falling asleep, repetitive behaviors/thoughts, appetite decrease, and irritability, while parents spontaneously reported moderate to severe AEs.

TL;DR: Risks of reduced growth rates should be balanced against expected benefits when preschool-age children are treated with stimulant medication.